Tag: FDA ANDA

30-Month Stay: How Patent Litigation Delays Generic Drug Approval

The 30-month stay under the Hatch-Waxman Act lets brand drug companies delay generic approval by triggering patent lawsuits. While designed to protect innovation, it's often used to extend monopolies, costing consumers billions annually.

Read More